SGLT2 Inhibitors Market Size, Share & Trends Analysis Report By Drug (Jardiance, Farxiga, Inpefa, Invokana), By Indication (Diabetes, Cardiovascular), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
SGLT2 Inhibitors Market Growth & Trends
The global SGLT2 inhibitors market size is anticipated t%li%reach USD 29.43 billion by 2030 and is expected t%li%expand at a CAGR of 7.71% during the forecast period, according t%li%a new report by Grand View Research, Inc. The recommendations and supportive guidelines from major health organizations, such as the American Diabetes Association (ADA), the European Association of for the Study of Diabetes (EASD), the European Society of Cardiology (ESC), and others have endorsed sodium-glucose cotransporter-2 (SGLT2) inhibitors for them beyond glucose control. For instance, in August 2023, the European Society of Cardiology (ESC) has issued a focused update t%li%their heart failure guidelines, integrating findings from nearly a dozen new clinical trials since 2021, such as EMPEROR-Preserved, DELIVER, STRONG-HF, and IRONMAN. Released at the ESC Congress 2023, the updated guidelines introduce new recommendations for the use of SGLT2 inhibitors in treating patients with heart failure with mildly reduced ejection fraction (HFmrEF).
In addition, the growing number of patients needing dialysis over the next few years showcased high demand of medicines such as SGLT2 inhibitors for treatment of CKD patients. In November 2023, the National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of empagliflozin, an SGLT2 inhibitor, for patients with chronic kidney disease (CKD). Empagliflozin has demonstrated efficacy in slowing the progression t%li%kidney failure and reducing the risk of heart attacks and strokes. NICE recommends making this treatment available t%li%patients across all stages of CKD. Such recommendations from drug regulatory agencies are expected t%li%boost demand for drugs during the forecast period.
The elder adults are more prone t%li%type 2 diabetes and heart failure, conditions where drugs have shown substantial benefits. This demographic shift increases the demand for effective treatments such as SGLT2 inhibitors. SGLT2 inhibitors are beneficial in reducing cardiovascular and renal risks, which are particularly prevalent in the elderly. This advantage makes these medications a preferred choice for older patients. According t%li%the World Health Organization (WHO), in 2022, around 1.4 billion people were aged 60 years and over, which was raised from 1 billion in 2020. In addition, WHO estimates that the elderly population is expected t%li%reach 2.1 billion. Thus, rising geriatric population is expected t%li%boost demand for SGLT2 inhibitors worldwide and drive market growth.
Increasing awareness of diabetes and significance of SGLT2 inhibitors in treatment among both patients and healthcare providers contribute t%li%higher prescription rates. For instance, in 2021, the WHO launched initiative “Global Diabetes Compact” t%li%raise awareness and improve patient access t%li%diabetic medicine including SGLT2 inhibitors and insulin. Such initiatives are expected t%li%boost adoption of SGLT2 inhibitors and open new opportunities in the market over the forecast period.
SGLT2 Inhibitors Market Report Highlights
SGLT2 Inhibitors Market Growth & Trends
The global SGLT2 inhibitors market size is anticipated t%li%reach USD 29.43 billion by 2030 and is expected t%li%expand at a CAGR of 7.71% during the forecast period, according t%li%a new report by Grand View Research, Inc. The recommendations and supportive guidelines from major health organizations, such as the American Diabetes Association (ADA), the European Association of for the Study of Diabetes (EASD), the European Society of Cardiology (ESC), and others have endorsed sodium-glucose cotransporter-2 (SGLT2) inhibitors for them beyond glucose control. For instance, in August 2023, the European Society of Cardiology (ESC) has issued a focused update t%li%their heart failure guidelines, integrating findings from nearly a dozen new clinical trials since 2021, such as EMPEROR-Preserved, DELIVER, STRONG-HF, and IRONMAN. Released at the ESC Congress 2023, the updated guidelines introduce new recommendations for the use of SGLT2 inhibitors in treating patients with heart failure with mildly reduced ejection fraction (HFmrEF).
In addition, the growing number of patients needing dialysis over the next few years showcased high demand of medicines such as SGLT2 inhibitors for treatment of CKD patients. In November 2023, the National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of empagliflozin, an SGLT2 inhibitor, for patients with chronic kidney disease (CKD). Empagliflozin has demonstrated efficacy in slowing the progression t%li%kidney failure and reducing the risk of heart attacks and strokes. NICE recommends making this treatment available t%li%patients across all stages of CKD. Such recommendations from drug regulatory agencies are expected t%li%boost demand for drugs during the forecast period.
The elder adults are more prone t%li%type 2 diabetes and heart failure, conditions where drugs have shown substantial benefits. This demographic shift increases the demand for effective treatments such as SGLT2 inhibitors. SGLT2 inhibitors are beneficial in reducing cardiovascular and renal risks, which are particularly prevalent in the elderly. This advantage makes these medications a preferred choice for older patients. According t%li%the World Health Organization (WHO), in 2022, around 1.4 billion people were aged 60 years and over, which was raised from 1 billion in 2020. In addition, WHO estimates that the elderly population is expected t%li%reach 2.1 billion. Thus, rising geriatric population is expected t%li%boost demand for SGLT2 inhibitors worldwide and drive market growth.
Increasing awareness of diabetes and significance of SGLT2 inhibitors in treatment among both patients and healthcare providers contribute t%li%higher prescription rates. For instance, in 2021, the WHO launched initiative “Global Diabetes Compact” t%li%raise awareness and improve patient access t%li%diabetic medicine including SGLT2 inhibitors and insulin. Such initiatives are expected t%li%boost adoption of SGLT2 inhibitors and open new opportunities in the market over the forecast period.
SGLT2 Inhibitors Market Report Highlights
- Jardiance (empagliflozin) segment dominated the market in 2023 and is anticipated t%li%grow significantly over the forecast period. This growth is attributed due t%li%increasing prevalence of diabetes, CKD, and cardiovascular conditions and high drug demand for treatment
- Type 2 diabetes segment dominated the market in 2023. This dominance is attributed due t%li%rising incidence of diabetes, increasing geriatric population, and increased prescription rate of drug
- Hospital pharmacies segment dominated the market in 2023. This dominance is attributed due t%li%increasing number hospitalization of diabetes, CKD, and heart failure patients for diagnosis and treatment
- North America dominated the market owing t%li%factors such as advanced healthcare infrastructure, rising prevalence of target diseases, and favorable regulatory environment
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug
1.2.2. Indication
1.2.3. Distribution Channel
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug and Indication outlook
2.2.2. Distribution Channel outlook
2.2.3. Regional outlook
2.3. Competitive Insights
CHAPTER 3. SGLT2 INHIBITORS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of target disease
3.2.1.2. Technological advancements in drug development
3.2.1.3. Growing awareness and diagnosis
3.2.2. Market restraint analysis
3.2.2.1. High cost of drug development
3.2.2.2. Stringent regulatory policies for drug approval
3.3. SGLT2 Inhibitors Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pipeline Analysis
3.3.4. Target population analysis
CHAPTER 4. SGLT2 INHIBITORS MARKET: DRUG ESTIMATES & TREND ANALYSIS
4.1. Global SGLT2 Inhibitors Market: Drug Dashboard
4.2. Global SGLT2 Inhibitors Market: Drug Movement Analysis
4.3. Global SGLT2 Inhibitors Market By Drug, Revenue
4.4. Jardiance (empagliflozin)
4.4.1. Jardiance (empagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Farxiga (dapagliflozin)
4.5.1. Farxiga (dapagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Invokana (canagliflozin)
4.6.1. Invokana (canagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Inpefa (sotagliflozin)
4.7.1. Inpefa (sotagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Qtern (dapagliflozin/saxagliptin)
4.8.1. Qtern (dapagliflozin/saxagliptin) market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Other SGLT2 Inhibitors
4.9.1. Other SGLT2 inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. SGLT2 INHIBITORS MARKET: INDICATION ESTIMATES & TREND ANALYSIS
5.1. Global SGLT2 Inhibitors Market: Indication Dashboard
5.2. Global SGLT2 Inhibitors Market: Indication Movement Analysis
5.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, By Indication, Revenue (USD Million)
5.4. Type 2 Diabetes
5.4.1. Type 2 diabetes market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Cardiovascular
5.5.1. Cardiovascular market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Chronic Kidney Disease (CKD)
5.6.1. Chronic kidney disease (CKD) market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Others
5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. SGLT2 INHIBITORS MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
6.1. Global SGLT2 Inhibitors Market: Distribution Channel Dashboard
6.2. Global SGLT2 Inhibitors Market: Distribution Channel Movement Analysis
6.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
6.4. Hospital Pharmacies
6.4.1. Hospital pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Online Pharmacies
6.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. SGLT2 INHIBITORS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY DRUG, INDICATION, AND DISTRIBUTION CHANNEL
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Boehringer Ingelheim International GmbH.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. AstraZeneca
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Merck & Co., Inc.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. TheracosBio, LLC
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Lexicon Pharmaceuticals, Inc.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Eli Lilly and Company
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Bristol-Myers Squibb Company
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Glenmark Pharmaceuticals Ltd
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug
1.2.2. Indication
1.2.3. Distribution Channel
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug and Indication outlook
2.2.2. Distribution Channel outlook
2.2.3. Regional outlook
2.3. Competitive Insights
CHAPTER 3. SGLT2 INHIBITORS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of target disease
3.2.1.2. Technological advancements in drug development
3.2.1.3. Growing awareness and diagnosis
3.2.2. Market restraint analysis
3.2.2.1. High cost of drug development
3.2.2.2. Stringent regulatory policies for drug approval
3.3. SGLT2 Inhibitors Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pipeline Analysis
3.3.4. Target population analysis
CHAPTER 4. SGLT2 INHIBITORS MARKET: DRUG ESTIMATES & TREND ANALYSIS
4.1. Global SGLT2 Inhibitors Market: Drug Dashboard
4.2. Global SGLT2 Inhibitors Market: Drug Movement Analysis
4.3. Global SGLT2 Inhibitors Market By Drug, Revenue
4.4. Jardiance (empagliflozin)
4.4.1. Jardiance (empagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Farxiga (dapagliflozin)
4.5.1. Farxiga (dapagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Invokana (canagliflozin)
4.6.1. Invokana (canagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Inpefa (sotagliflozin)
4.7.1. Inpefa (sotagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Qtern (dapagliflozin/saxagliptin)
4.8.1. Qtern (dapagliflozin/saxagliptin) market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Other SGLT2 Inhibitors
4.9.1. Other SGLT2 inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. SGLT2 INHIBITORS MARKET: INDICATION ESTIMATES & TREND ANALYSIS
5.1. Global SGLT2 Inhibitors Market: Indication Dashboard
5.2. Global SGLT2 Inhibitors Market: Indication Movement Analysis
5.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, By Indication, Revenue (USD Million)
5.4. Type 2 Diabetes
5.4.1. Type 2 diabetes market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Cardiovascular
5.5.1. Cardiovascular market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Chronic Kidney Disease (CKD)
5.6.1. Chronic kidney disease (CKD) market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Others
5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. SGLT2 INHIBITORS MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
6.1. Global SGLT2 Inhibitors Market: Distribution Channel Dashboard
6.2. Global SGLT2 Inhibitors Market: Distribution Channel Movement Analysis
6.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
6.4. Hospital Pharmacies
6.4.1. Hospital pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Online Pharmacies
6.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. SGLT2 INHIBITORS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY DRUG, INDICATION, AND DISTRIBUTION CHANNEL
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Boehringer Ingelheim International GmbH.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. AstraZeneca
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Merck & Co., Inc.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. TheracosBio, LLC
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Lexicon Pharmaceuticals, Inc.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Eli Lilly and Company
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Bristol-Myers Squibb Company
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Glenmark Pharmaceuticals Ltd
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
LIST OF TABLES
Table 1 List of abbreviation
Table 2 North America SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
Table 3 North America SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 4 North America SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 5 North America SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 6 U.S. SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 7 U.S. SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 8 U.S. SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 9 Canada SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 10 Canada SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 11 Canada SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 12 Mexico SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 13 Mexico SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 14 Mexico SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 15 Europe SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
Table 16 Europe SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 17 Europe SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 18 Europe SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 19 Germany SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 20 Germany SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 21 Germany SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 22 UK SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 23 UK SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 24 UK SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 25 France SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 26 France SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 27 France SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 28 Italy SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 29 Italy SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 30 Italy SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 31 Spain SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 32 Spain SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 33 Spain SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 34 Denmark SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 35 Denmark SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 36 Denmark SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 37 Sweden SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 38 Sweden SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 39 Sweden SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 40 Norway SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 41 Norway SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 42 Norway SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 43 Asia Pacific SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
Table 44 Asia Pacific SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 45 Asia Pacific SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 46 Aisa Pacific SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 47 China SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 48 China SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 49 China SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 50 Japan SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 51 Japan SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 52 Japan SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 53 India SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 54 India SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 55 India SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 56 South Korea SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 57 South Korea SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 58 South Korea SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 59 Australia SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 60 Australia SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 61 Australia SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 62 Thailand SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 63 Thailand SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 64 Thailand SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 65 Latin America SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
Table 66 Latin America SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 67 Latin America SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 68 Latin America SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 69 Brazil SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 70 Brazil SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 71 Brazil SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 72 Argentina SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 73 Argentina SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 74 Argentina SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 75 MEA SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
Table 76 MEA SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 77 MEA SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 78 MEA SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 79 South Africa SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 80 South Africa SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 81 South Africa SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 85 UAE SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 86 UAE SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 87 UAE SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 88 Kuwait SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 89 Kuwait SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 90 Kuwait SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 1 List of abbreviation
Table 2 North America SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
Table 3 North America SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 4 North America SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 5 North America SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 6 U.S. SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 7 U.S. SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 8 U.S. SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 9 Canada SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 10 Canada SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 11 Canada SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 12 Mexico SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 13 Mexico SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 14 Mexico SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 15 Europe SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
Table 16 Europe SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 17 Europe SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 18 Europe SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 19 Germany SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 20 Germany SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 21 Germany SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 22 UK SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 23 UK SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 24 UK SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 25 France SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 26 France SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 27 France SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 28 Italy SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 29 Italy SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 30 Italy SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 31 Spain SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 32 Spain SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 33 Spain SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 34 Denmark SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 35 Denmark SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 36 Denmark SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 37 Sweden SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 38 Sweden SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 39 Sweden SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 40 Norway SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 41 Norway SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 42 Norway SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 43 Asia Pacific SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
Table 44 Asia Pacific SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 45 Asia Pacific SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 46 Aisa Pacific SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 47 China SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 48 China SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 49 China SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 50 Japan SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 51 Japan SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 52 Japan SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 53 India SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 54 India SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 55 India SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 56 South Korea SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 57 South Korea SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 58 South Korea SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 59 Australia SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 60 Australia SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 61 Australia SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 62 Thailand SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 63 Thailand SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 64 Thailand SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 65 Latin America SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
Table 66 Latin America SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 67 Latin America SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 68 Latin America SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 69 Brazil SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 70 Brazil SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 71 Brazil SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 72 Argentina SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 73 Argentina SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 74 Argentina SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 75 MEA SGLT2 Inhibitors market, by region, 2018 - 2030 (USD Million)
Table 76 MEA SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 77 MEA SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 78 MEA SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 79 South Africa SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 80 South Africa SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 81 South Africa SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 85 UAE SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 86 UAE SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 87 UAE SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
Table 88 Kuwait SGLT2 Inhibitors market, by drug, 2018 - 2030 (USD Million)
Table 89 Kuwait SGLT2 Inhibitors market, by indication, 2018 - 2030 (USD Million)
Table 90 Kuwait SGLT2 Inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 North America Biotechnology and Pharmaceutical Services Outsourcing, Market Segmentation
Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 10 Porter’s Five Forces Analysis
Fig. 11 Regional Marketplace: Key Takeaways
Fig. 12 North America Biotechnology and Pharmaceutical Services Outsourcing, for Consulting, 2018 - 2030 (USD Million)
Fig. 13 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Consulting, 2018 - 2030 (USD Million)
Fig. 14 North America Biotechnology and Pharmaceutical Services Outsourcing, for Clinical Development Consulting, 2018 - 2030 (USD Million)
Fig. 15 North America Biotechnology and Pharmaceutical Services Outsourcing, for Strategic Planning & Business Development Consulting, 2018 - 2030 (USD Million)
Fig. 16 North America Biotechnology and Pharmaceutical Services Outsourcing, for Quality Management Systems Consulting, 2018 - 2030 (USD Million)
Fig. 17 North America Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
Fig. 18 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Affairs, 2018 - 2030 (USD Million)
Fig. 19 North America Biotechnology and Pharmaceutical Services Outsourcing, for Legal Representation, 2018 - 2030 (USD Million)
Fig. 20 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
Fig. 21 North America Biotechnology and Pharmaceutical Services Outsourcing, for Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
Fig. 22 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Submissions, 2018 - 2030 (USD Million)
Fig. 23 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Operations, 2018 - 2030 (USD Million)
Fig. 24 North America Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
Fig. 25 North America Biotechnology and Pharmaceutical Services Outsourcing, for Product Design & Development, 2018 - 2030 (USD Million)
Fig. 26 North America Biotechnology and Pharmaceutical Services Outsourcing, for Research, Strategy, & Concept Generation, 2018 - 2030 (USD Million)
Fig. 27 North America Biotechnology and Pharmaceutical Services Outsourcing, for Concept & Requirements Development, 2018 - 2030 (USD Million)
Fig. 28 North America Biotechnology and Pharmaceutical Services Outsourcing, for Detailed Design & Process Development, 2018 - 2030 (USD Million)
Fig. 29 North America Biotechnology and Pharmaceutical Services Outsourcing, for Design Verification & Validation, 2018 - 2030 (USD Million)
Fig. 30 North America Biotechnology and Pharmaceutical Services Outsourcing, for Process Validation & Manufacturing Transfer, 2018 - 2030 (USD Million)
Fig. 31 North America Biotechnology and Pharmaceutical Services Outsourcing, for Production & Commercial Support, 2018 - 2030 (USD Million)
Fig. 32 North America Biotechnology and Pharmaceutical Services Outsourcing, for Auditing and Assessment, 2018 - 2030 (USD Million)
Fig. 33 North America Biotechnology and Pharmaceutical Services Outsourcing, for General Auditing, 2018 - 2030 (USD Million)
Fig. 34 North America Biotechnology and Pharmaceutical Services Outsourcing, for Gap Assessments, 2018 - 2030 (USD Million)
Fig. 35 North America Biotechnology and Pharmaceutical Services Outsourcing, for Due Diligence Assessments, 2018 - 2030 (USD Million)
Fig. 36 North America Biotechnology and Pharmaceutical Services Outsourcing, for Mock Audits/Inspections, 2018 - 2030 (USD Million)
Fig. 37 North America Biotechnology and Pharmaceutical Services Outsourcing, for Inspection/Audit Management and Support, 2018 - 2030 (USD Million)
Fig. 38 North America Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
Fig. 39 North America Biotechnology and Pharmaceutical Services Outsourcing, for Product Maintenance, 2018 - 2030 (USD Million)
Fig. 40 North America Biotechnology and Pharmaceutical Services Outsourcing, for Training & Education, 2018 - 2030 (USD Million)
Fig. 41 North America Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
Fig. 42 North America Biotechnology and Pharmaceutical Services Outsourcing, for Pharmaceutical Companies, 2018 - 2030 (USD Million)
Fig. 43 North America Biotechnology and Pharmaceutical Services Outsourcing, for Biotech Companies, 2018 - 2030 (USD Million)
Fig. 44 Country Outlook, 2023 & 2030
Fig. 45 U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 46 Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 47 Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 48 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 North America Biotechnology and Pharmaceutical Services Outsourcing, Market Segmentation
Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 10 Porter’s Five Forces Analysis
Fig. 11 Regional Marketplace: Key Takeaways
Fig. 12 North America Biotechnology and Pharmaceutical Services Outsourcing, for Consulting, 2018 - 2030 (USD Million)
Fig. 13 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Consulting, 2018 - 2030 (USD Million)
Fig. 14 North America Biotechnology and Pharmaceutical Services Outsourcing, for Clinical Development Consulting, 2018 - 2030 (USD Million)
Fig. 15 North America Biotechnology and Pharmaceutical Services Outsourcing, for Strategic Planning & Business Development Consulting, 2018 - 2030 (USD Million)
Fig. 16 North America Biotechnology and Pharmaceutical Services Outsourcing, for Quality Management Systems Consulting, 2018 - 2030 (USD Million)
Fig. 17 North America Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
Fig. 18 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Affairs, 2018 - 2030 (USD Million)
Fig. 19 North America Biotechnology and Pharmaceutical Services Outsourcing, for Legal Representation, 2018 - 2030 (USD Million)
Fig. 20 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
Fig. 21 North America Biotechnology and Pharmaceutical Services Outsourcing, for Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
Fig. 22 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Submissions, 2018 - 2030 (USD Million)
Fig. 23 North America Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Operations, 2018 - 2030 (USD Million)
Fig. 24 North America Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
Fig. 25 North America Biotechnology and Pharmaceutical Services Outsourcing, for Product Design & Development, 2018 - 2030 (USD Million)
Fig. 26 North America Biotechnology and Pharmaceutical Services Outsourcing, for Research, Strategy, & Concept Generation, 2018 - 2030 (USD Million)
Fig. 27 North America Biotechnology and Pharmaceutical Services Outsourcing, for Concept & Requirements Development, 2018 - 2030 (USD Million)
Fig. 28 North America Biotechnology and Pharmaceutical Services Outsourcing, for Detailed Design & Process Development, 2018 - 2030 (USD Million)
Fig. 29 North America Biotechnology and Pharmaceutical Services Outsourcing, for Design Verification & Validation, 2018 - 2030 (USD Million)
Fig. 30 North America Biotechnology and Pharmaceutical Services Outsourcing, for Process Validation & Manufacturing Transfer, 2018 - 2030 (USD Million)
Fig. 31 North America Biotechnology and Pharmaceutical Services Outsourcing, for Production & Commercial Support, 2018 - 2030 (USD Million)
Fig. 32 North America Biotechnology and Pharmaceutical Services Outsourcing, for Auditing and Assessment, 2018 - 2030 (USD Million)
Fig. 33 North America Biotechnology and Pharmaceutical Services Outsourcing, for General Auditing, 2018 - 2030 (USD Million)
Fig. 34 North America Biotechnology and Pharmaceutical Services Outsourcing, for Gap Assessments, 2018 - 2030 (USD Million)
Fig. 35 North America Biotechnology and Pharmaceutical Services Outsourcing, for Due Diligence Assessments, 2018 - 2030 (USD Million)
Fig. 36 North America Biotechnology and Pharmaceutical Services Outsourcing, for Mock Audits/Inspections, 2018 - 2030 (USD Million)
Fig. 37 North America Biotechnology and Pharmaceutical Services Outsourcing, for Inspection/Audit Management and Support, 2018 - 2030 (USD Million)
Fig. 38 North America Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
Fig. 39 North America Biotechnology and Pharmaceutical Services Outsourcing, for Product Maintenance, 2018 - 2030 (USD Million)
Fig. 40 North America Biotechnology and Pharmaceutical Services Outsourcing, for Training & Education, 2018 - 2030 (USD Million)
Fig. 41 North America Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
Fig. 42 North America Biotechnology and Pharmaceutical Services Outsourcing, for Pharmaceutical Companies, 2018 - 2030 (USD Million)
Fig. 43 North America Biotechnology and Pharmaceutical Services Outsourcing, for Biotech Companies, 2018 - 2030 (USD Million)
Fig. 44 Country Outlook, 2023 & 2030
Fig. 45 U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 46 Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 47 Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 48 Puerto Rico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
